Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study Authors: Yasuyoshi Kimura, Toru Koda, Hiroyuki Kurakami, Shigeru Sakamoto, Koji Iwasaki, Kanako Asai, Lindun Ge, Hiroki Kato, Takashi Tsuboi, Noriyuki Matsukawa, Osamu Kano, Dai Matsuse, Masahiko Tomiyama, Masaru Yokoe, Yoshitaka Nagai, Hideki Mochizuki Published: 2025 ABSTRACT AbstractIntroductionAccumulating evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may have therapeutic effects against Parkinson’s disease (PD); however, clinical evidence has not yet been established and remains controversial. This clinical study aims to assess the efficacy, disease-modifying effects, safety and optimal dose of oral semaglutide tablets, a GLP-1 receptor agonist, in idiopathic patients with PD.Methods and analysisThe MOST-ABLE study is a phase 2, multicentre, double-blind, randomised, placebo-controlled trial of oral semaglutide tablets in 99 participants with PD. Patients with PD (Hoehn & Yahr stages 1–2.5) at eight sites in Japan will be randomly assigned in a 1:1:1 ratio to one of three groups: oral semaglutide tablets (7 mg or 14 mg) or placebo. The study drugs will be administered once daily as an add-on to conventional medical treatment for PD. After 36 weeks of treatment, the participants will be treated without the study drugs for 12 weeks. The efficacy outcomes include Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Parkinson’s Disease Questionnaire-39, cognitive tests and dopamine transporter imaging. The primary endpoint is the change in the MDS-UPDRS part 3 score in the practically defined off-medication state from baseline at 48 weeks between the treatment allocation groups. The safety and tolerability will also be evaluated.Ethics and disseminationThe study protocol was approved by the Pharmaceuticals and Medical Devices Agency of Japan and the study was approved by the institutional review boards at the University of Osaka Hospital and each study site. All participants are required to provide informed consent. The results will be disseminated in peer-reviewed journals, presented at scientific meetings and presented to patients in a lay summary format.Trial registration numberjRCT2051230090 (https://jrct.mhlw.go.jp/latest-detail/jRCT2051230090), universal trial number U1111-1271-3794.Keywords: Parkinson-s disease, Clinical Protocols, Randomized Controlled Trial Strengths and limitations of this study This phase 2, double-blind, randomised, placebo-controlled trial will assess the effects of oral semaglutide tablets in Parkinson’s disease in Japan. This phase 2, double-blind, randomised, placebo-controlled trial will assess the effects of oral semaglutide tablets in Parkinson’s disease in Japan. Using clinically defined off-state motor symptoms following the washout period as the primary outcome may enable the evaluation of potential disease-modifying effects. Using clinically defined off-state motor symptoms following the washout period as the primary outcome may enable the evaluation of potential disease-modifying effects. The three-group design and plasma semaglutide measurements will provide insights into the relationship between dosage and efficacy. The three-group design and plasma semaglutide measurements will provide insights into the relationship between dosage and efficacy. Limitations of the study include its relatively small size and the short (36-week) duration of exposure to the investigational drug. Limitations of the study include its relatively small size and the short (36-week) duration of exposure to the investigational drug. Introduction Parkinson’s disease (PD) is a common neurodegenerative disorder, affecting approximately 11.8 million people worldwide as of 2021, with the number of people living with the disease projected to reach about 25.2 million by 2050.1 Patients with PD suffer worsening motor symptoms (tremor, rigidity, bradykinesia, gait disturbance and instability) alongside multiple non-motor symptoms (such as autonomic symptoms, depression, fatigue, pain, sleep disturbance, hallucinations and cognitive impairment), leading to disability and death.2 Current symptomatic treatment primarily alleviates motor symptoms; however, no disease-modifying therapy (DMT) that slows or halts disease progression is currently available.3 The stark rise in prevalence, and its impacts on patients, caregivers, social welfare and medical economy, underscores an urgent need for DMT development. Glucagon-like peptide-1 (GLP-1) receptor agonists, initially approved for type 2 diabetes mellitus (T2DM), have shown multiple beneficial effects on chronic conditions and hold potential as neuroprotective agents.4 5 GLP-1 receptors are expressed on neurons and glia within the brain, and GLP-1 receptor agonists demonstrate neuroprotective effects in animal models of PD by modulating neuroinflammation, inhibiting the progression of α-synuclein pathology and suppressing neuronal cell death.6 7 Systematic meta-analyses in rodent PD models have demonstrated significant improvements in dopaminergic neurotransmission and motor outcomes.8 In addition to basic research, epidemiological studies have indicated that T2DM patients treated with GLP-1 receptor agonists have a lower incidence of PD compared with users of other antidiabetic medications.9 10 These data support the promise of GLP-1 receptor agonists as disease-modifying agents for PD; however, clinical trial results remain inconclusive and are subject to debate. Exenatide subcutaneous injection (tray preparation administered for 48 weeks followed by a 12-week washout) demonstrated efficacy in suppressing motor symptom progression by achieving primary endpoints in the phase 2 randomised controlled trial (RCT)11; however, the phase 3 RCT (continuous treatment for 96 weeks using the prefilled pen device) failed to demonstrate efficacy.12 NLY01, a pegylated exenatide formulation with enhanced brain permeability and prolonged duration of action, failed to meet its primary endpoint in the phase 2 RCT for PD, but showed potential efficacy in the subgroup of patients under 60 years of age.13 Meanwhile, the phase 2 RCT of lixisenatide for PD met its primary endpoint, demonstrating a suppression in the progression of motor symptoms in PD.14 The results of a phase 3 trial of exenatide were disappointing. However, based on the strength of evidence from basic research and epidemiological data, as well as the mixed clinical trial results, it is conceivable that differences between GLP-1 receptor agonists and diversity within the PD subgroups may have influenced trial outcomes. Notably, liraglutide and its long-acting derivative semaglutide share structural similarities but exhibit different distributions within the rodent brain.15 This suggests that differences may arise not only in brain penetration but also in target engagement depending on the drug and its delivery system, justifying the value of testing different drugs in clinical trials. Peripheral metabolic dysfunction, including insulin resistance and dyslipidaemia, as well as the accompanying increase in peripheral inflammatory cytokines, contributes to neurodegeneration.16 Metabolic dysfunction and peripheral inflammatory changes may play a significant role in certain subgroups of PD patients, and GLP-1 receptor agonists may demonstrate efficacy in such patients through both central and peripheral actions. This also explains why epidemiological studies in patients with T2DM have consistently shown an association between GLP-1 receptor agonists and a reduced incidence of PD. In patients with T2DM, semaglutide exhibits stronger peripheral anti-inflammatory effects than placebo or exenatide17 and has been shown to reduce the risk of developing Alzheimer’s disease more significantly than other GLP-1 receptor agonists.18 Therefore, we are conducting a double-blind, randomised controlled study to investigate the disease-modifying effects, safety, and optimal dose of oral semaglutide tablets in patients with PD (MOST-ABLE study). To the best of our knowledge, this is the world’s first phase 2 RCT testing oral semaglutide tablets in patients with PD, addressing both mechanistic plausibility and unmet clinical needs. Since patients with PD suffer from motor symptoms, oral formulations offer advantages over subcutaneous injection formulations. The promising preclinical data, epidemiologic associations and inconclusive clinical trial results so far across GLP-1 agents create a compelling rationale for rigorously testing oral semaglutide to clarify its disease-modifying potential in PD. Methods and analysis Trial design The MOST-ABLE study is a three-group, parallel, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial with two intervention groups (semaglutide tablets 7 mg and 14 mg) and one control group (placebo) in a 1:1:1 allocation with stratified/two blocks by Hoehn and Yahr stage (1.0–1.5 or 2.0–2.5). The trial period will include a 36-week exposure period, including a titration period and a 12-week washout period. Participants will visit the hospital for screening and registration at baseline and 4, 8, 12, 24, 36 and 48 weeks (figure 1). Detailed evaluations will be performed at screening, baseline and at 12, 24, 36 and 48 weeks. Cognitive tests (Montreal Cognitive Assessment, Symbol Digit Modality Test (SDMT), digit span, noise pareidolia test (NPT)) will be performed only at baseline and 48 weeks. When a subject discontinues the clinical trial, an evaluation at the time of discontinuation should be conducted at the site, if possible. Dopamine transporter imaging will be administered for the first time on the baseline or up to 4 weeks prior, and for the second time at the 48 week visit or up to 4 weeks later. Up to 99 participants will be registered in the trial. This protocol is reported following the Standard Protocol Items: Recommendations for Interventional Trials checklist.19 The outline of the protocol was accepted by the Pharmaceuticals and Medical Devices Agency in Japan. Outline of the trial design. Allowances for visits and clinical assessments. The allowances for DaTSCAN are set at baseline: −28 days and visit 7: +28 days. Among outcome evaluation, cognitive tests (Montreal Cognitive Assessment, symbol digit modality test, digit span, noise pareidolia test) are evaluated only at baseline and 48 weeks. Outcomes Primary outcomes Changes in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part 3 score in the practically defined OFF medication state from baseline to 48 weeks will be compared between participants according to treatment allocation. The MDS-UPDRS has four parts20 21: part 1 (non-motor experiences of daily living), part 2 (motor experiences of daily living), part 3 (motor examinations) and part 4 (motor complications). The MDS-UPDRS consists of five measures, 0 (normal) to 4 (severe), according to each item, and is evaluated as the total score per part of parts 1–4. The MDS-UPDRS part 3 will be evaluated by investigators (evaluators) with certificates from the MDS. In this setting, the MDS-UPDRS part 3 has high test–retest reliability and high inter-rater and intrarater reliability with minimum and maximum values of 0 and 132, respectively, where higher scores are indicative of worse outcomes. In this trial, the practically defined OFF medication state is defined as the state in which the participants have had no medication for more than 12 hours. Secondary outcomes Safety and tolerability of semaglutide (time points: 0, 4, 8, 12, 24, 36 and 48 weeks, depending on the item) To evaluate the safety and tolerability of the study drugs, the following information will be collected. Adverse events, adherence to study drugs, vital signs, body weight, body mass index (BMI), blood tests, HbA1c (0 and 48 weeks), Council on Nutrition Appetite Questionnaire-Japanese, and the Japanese version of the Columbia Suicide Severity Rating Scale (C-SSRS). Several contents in this item, which may affect the masking, will be collected by the investigators who do not evaluate efficacy outcomes. Change in the MDS-UPDRS part 3 score (time frame: 36 weeks) Changes in the MDS-UPDRS part 3 score in the practically defined OFF-medication state from baseline at 36 weeks will be compared between participants according to treatment allocation. Changes in the MDS-UPDRS parts 1, 2, 3 and 4 scores in the ON medication state (time frame: 36 and 48 weeks) Changes in the MDS-UPDRS parts 1, 2, 3 and 4 scores in the ON medication state from baseline at 36 and 48 weeks will be compared between the participants according to treatment allocation. For the MDS-UPDRS part 3 measurement, the ON medication state is defined as the state 1–2 hours after the participants take their regular morning medication. Change in the Japanese version of the Parkinson’s Disease Questionnaires-39 score (time frame: 36 and 48 weeks) Changes in the Japanese version of the Parkinson’s Disease Questionnaires-39 score from baseline to 36 and 48 weeks are to be compared among the participants according to treatment allocation. This questionnaire assesses how often people affected by Parkinson’s experience difficulties across eight dimensions of daily living. The 39-item questionnaire offers a patient-reported measure of health status and quality of life and is the most frequently used disease-specific health status measure. Higher scores indicate worse outcomes. Change in the Montreal Cognitive Assessment-Japanese score (time frame: 48 weeks) Changes in the Montreal Cognitive Assessment-Japanese score from baseline to 48 weeks will be compared between participants according to treatment allocation. The raters will evaluate cognitive functions, such as attention and concentration, memory, language, conceptual thinking, calculations and orientation. The execution time takes approximately 10 min and will be evaluated as the sum of the scores for each item. A score of 30 points or more is considered normal. Change in the SDMT score (time frame: 48 weeks) Changes in SDMT scores from baseline to 48 weeks will be compared between participants according to treatment allocation. The SDMT is a test of information processing speed as a marker of cognitive function. The number of correct answers within 90 s is evaluated. Change in the digit span score (time frame: 48 weeks) The change in the Digit Span task score from baseline to 48 weeks will be compared between participants according to treatment allocation. The Digit Span Forward (DSF) test requires participants to repeat numbers in the same order as read by the examiner. The DSF measures short-term memory. Digit Span Backward (DSB) requires participants to repeat the numbers in the reverse order of those presented by the examiner. The DSB measures auditory working memory. Every item on the Digit Span in the Wechsler Adult Intelligence Scale-IV consists of two trials, each scored 1 or 0 points. A minimum value of 0 and a maximum value of 16 can be obtained for each task. Higher scores indicated better outcomes. Change in the NPT score (time frame: 48 weeks) Changes in the NPT score from baseline at 48 weeks will be compared between participants according to treatment allocation. The NPT is a test for pareidolias and visual hallucinations, with a minimum and maximum value of 0 and 32 for noise pareidolia score, respectively, and 0 and 8 for missing score, respectively. Higher scores indicate worse outcomes. Change in the Japanese version of the Patient Health Questionnaire-9 score (time frame: 48 weeks) Changes in the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) score from baseline to 48 weeks will be compared between participants according to treatment allocation. The PHQ-9 will be used to assess depression. Depression Severity: 0–4, none; 5–9, mild; 10–14, moderate; 15–19, moderately severe; 20–27, severe. Max Score, 27. Higher scores indicate worse outcomes. Patient Global Impression Change Score (time frame: 36 and 48 weeks) Patient Global Impression Change scores at 36 and 48 weeks will be compared between participants according to treatment allocation. Levodopa equivalent daily dose (time frames: 0, 4, 8, 12, 24, 36 and 48 weeks) The levodopa equivalent daily dose and changes in the anti-PD drugs will be assessed and recorded by the research team. Quantitative change in dopamine transporter availability (time Frame: 48 weeks) Quantitative changes in dopamine transporter availability, as measured by DaTscan uptake (specific binding ratio) from baseline or up to 4 weeks prior to 48–52 weeks, will be compared between participants according to treatment allocation. Explanatory outcomes Plasma semaglutide concentration at 36-week visit Video recording of the evaluation of MDS-UPDRS part 3 in the clinically defined OFF state for an optional follow-up observational study Off-period video recordings are conducted for the participants who consented to participate in the follow-up observational study. Evaluations will be performed during the trial period and 2 years after the initiation of the investigational drug. Participants Patients with PD who meet the following criteria are eligible. Inclusion criteria Male and female patients aged 20–80. Male and female patients aged 20–80. The diagnosis of PD by a neurologist according to one of the following diagnostic criteria: UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria, International Parkinson and MDS clinical diagnostic criteria for PD (clinically established PD in MDS-PD criteria), and MDS clinically established early PD criteria (MDS-early PD criteria). The diagnosis of PD by a neurologist according to one of the following diagnostic criteria: UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria, International Parkinson and MDS clinical diagnostic criteria for PD (clinically established PD in MDS-PD criteria), and MDS clinically established early PD criteria (MDS-early PD criteria). Modified Hoehn and Yahr stage less than or equal to 2.5 in the ON medication state. Modified Hoehn and Yahr stage less than or equal to 2.5 in the ON medication state. Participants who have been taking stable doses of anti-PD medications for at least 4 weeks before enrolment. The dose of monoamine oxidase B (MAO-B) inhibitors (selegiline, rasagiline and safinamide) must be stable for at least 12 weeks. Participants who have been taking stable doses of anti-PD medications for at least 4 weeks before enrolment. The dose of monoamine oxidase B (MAO-B) inhibitors (selegiline, rasagiline and safinamide) must be stable for at least 12 weeks. Documented informed consent to participate. Documented informed consent to participate. Exclusion criteria Diagnosis or suspicion of other causes for Parkinsonism. Diagnosis or suspicion of other causes for Parkinsonism. Diagnosis of genetic PD. Diagnosis of genetic PD. Patients who have a brain abnormality pointed out by CT or MRI, which may affect the result of DaTscan. Patients who have a brain abnormality pointed out by CT or MRI, which may affect the result of DaTscan. Patients unable to attend the clinic visits in the practically defined OFF medication state. Patients unable to attend the clinic visits in the practically defined OFF medication state. Concurrent severe depression is defined by a score ≥16 on the J-PHQ-9. Concurrent severe depression is defined by a score ≥16 on the J-PHQ-9. Significant cognitive impairment defined by a score <24 on the Mini–Mental State Examination-Japanese or a score <12 on the Frontal Assessment Battery-Japanese. Significant cognitive impairment defined by a score <24 on the Mini–Mental State Examination-Japanese or a score <12 on the Frontal Assessment Battery-Japanese. Prior intracerebral surgical intervention for PD, including deep brain stimulation. Prior intracerebral surgical intervention for PD, including deep brain stimulation. Treated by levodopa-carbidopa continuous infusion gel therapy. Treated by levodopa-carbidopa continuous infusion gel therapy. Previous participation in one of the following PD trials (Biogen SPARK trial, Prothena Pasadena trial, Sanofi Genzyme MOVES-PD trial, Ursodeoxycholic acid in PD [UP] study or any other trial still considered to involve a potentially PD-modifying agent). Previous participation in one of the following PD trials (Biogen SPARK trial, Prothena Pasadena trial, Sanofi Genzyme MOVES-PD trial, Ursodeoxycholic acid in PD [UP] study or any other trial still considered to involve a potentially PD-modifying agent). Participation in another clinical trial of a device, drug or surgical treatment. Participation in another clinical trial of a device, drug or surgical treatment. BMI<18.5. BMI<18.5. T1DM or T2DM. T1DM or T2DM. Severe gastrointestinal disease (e.g. gastroparesis) or gastrectomy. Severe gastrointestinal disease (e.g. gastroparesis) or gastrectomy. History of pancreatitis. History of pancreatitis. Severe impaired renal function with eGFR <30 mL/min. Severe impaired renal function with eGFR <30 mL/min. Decompensated liver cirrhosis. Decompensated liver cirrhosis. History or suspicion of thyroid cancer. History or suspicion of thyroid cancer. History or family history of Multiple Endocrine Neoplasia 2 syndrome. History or family history of Multiple Endocrine Neoplasia 2 syndrome. Females who are pregnant or breastfeeding. Females who are pregnant or breastfeeding. Participants who have oral medication when waking up. Participants who have oral medication when waking up. Participants who have night meals or medications within 8 hours before study drug intake. Participants who have night meals or medications within 8 hours before study drug intake. Previous exposure to GLP-1 receptor agonists, including semaglutide. Previous exposure to GLP-1 receptor agonists, including semaglutide. Hypersensitivity to any of Rybelsus’s excipients. Hypersensitivity to any of Rybelsus’s excipients. High risk of suicide defined by suicidal ideation on C-SSRS or history of suicide. High risk of suicide defined by suicidal ideation on C-SSRS or history of suicide. Any medical or psychiatric condition or previous conventional/experimental treatment which, in the investigator’s opinion, compromises the potential participant’s ability to participate. Any medical or psychiatric condition or previous conventional/experimental treatment which, in the investigator’s opinion, compromises the potential participant’s ability to participate. Recruitment Participants were recruited from eight study sites in Japan: Hirosaki University Hospital (Aomori, Japan), Kindai University Hospital (Osaka, Japan), Kyushu University Hospital (Fukuoka, Japan), Nagoya City University Hospital (Aichi, Japan), Nagoya University Hospital (Aichi, Japan), University of Osaka Hospital (Osaka, Japan), Toho University Omori Medical Center (Tokyo, Japan) and Toyonaka Municipal Hospital (Osaka, Japan). The recruitment rates were monitored throughout the trial and shared with the trial sites. Recruitment for this trial was conducted from 6 November 2023 to 30 September 2024. All clinical data collection, including plasma semaglutide concentrations, will be completed by November to December 2025, and the study will be completed by March 2026. The assessment of the optional follow-up study will be completed in November 2026. Randomisation A randomisation list and sealed codes for emergency unblinding were prepared by unblinded investigators. The randomisation programme has been prepared using Electronic Data Capture (EDC, Fauntayn provided by Clin Cloud). on enrolment, each participant will be stratified into two blocks based on the Hoehn and Yahr stage (1.0–1.5 or 2.0–2.5), and randomisation is to be performed using the EDC system. The blind study drugs were delivered to the corresponding study site. Participants, investigators and outcome assessors, data analysts will be blinded after assignment to interventions. Emergency key opening is permitted only in emergencies, such as when a subject experiences a serious adverse event requiring appropriate medical treatment and it becomes necessary to identify the specific intervention administered to the subject. Under these circumstances, the principal investigator at the facility shall perform an emergency key open on the EDC system after obtaining permission to open from the coordinating investigator. Study drugs and dosing The investigational drugs, including placebo tablets, were provided free of charge by Novo Nordisk based on the review and agreement of the physician-initiated trial protocol. The investigational drug administration schedule for each group is as follows. Arm 1: Semaglutide 7 mg: Oral semaglutide (3 mg for 4 weeks, followed by 7 mg for 32 weeks, and a washout period of 12 weeks) administered once daily as an add-on to conventional medical treatment for PD. Arm 2: Semaglutide 14 mg: Oral semaglutide (3 mg for 4 weeks, followed by 7 mg for 4 weeks, and finally 14 mg for 28 weeks, with a washout period of 12 weeks) administered once daily as an add-on to the conventional medical treatment for PD. Arm 3: Placebo comparator: Oral semaglutide placebo (placebo for 36 weeks, followed by a washout period of 12 weeks) administered once daily as an add-on to conventional medical treatment for PD. If the investigational drug becomes intolerable, discontinue administration without reducing the dose. When adverse events such as gastrointestinal symptoms occur after initiation or dose escalation of the investigational drug, it is possible to conduct medical care, gather information on the adverse events and administer symptomatic treatment within the scope not contraindicated for concomitant use. Compliance with administration We provide the subject with the medication instructions and explain them. Compliance with the administration of investigational drugs is assessed by counting unused tablets brought by the subject at the visit and recorded in the source documents and related forms. Data management All participant data relating to the study will be recorded on printed or electronic case report forms unless transmitted to the sponsor-investigator or designee electronically. Participants will be assigned a unique identifier and any participant records or datasets that are transferred to the sponsor-investigator or designee will contain the identifier only. Records and documents pertaining to the conduct of this study must be retained by the investigator until the day on which the investigational product provider receives marketing approval of the test drug (or the day 3 years after the date of notification in the case of a notification pursuant to Good Clinical Practice (GCP Article 26–10, Paragraph 3) or the day 3 years after the date of premature termination or completion of the clinical trial, whichever comes later, unless local regulations or institutional policies require a longer retention period. The investigator permits study-related monitoring, audits, IRB/IEC review and regulatory agency inspections. Monitoring is conducted by personnel designated by the study coordinator at each site every 1–3 months. Sample size determination According to the regulatory science consultation with the Pharmaceuticals and Medical Devices Agency in Japan, three arms are set up in this study to explore the optimal dose, efficacy and safety. The sample size is based on the detectable effect size (primary outcome is a change in the MDS-UPDRS part 3 score in the OFF medication state) for this three-arm (semaglutide vs placebo) parallel-group trial design. To determine the sample size, we refer to the previous clinical trials of exenatide on PD.11 Required sample size is 66–87 when we set the following parameters: (1) Difference of change in MDS-UPDRS part 3 placebo vs 7 mg is 0–6 and placebo vs 14 mg is 6, (2) Analysis: regression analysis of covariance (ANCOVA) approach, (3) Adjustment: stratification factors (Hoehn and Yahr stage) and baseline raw MDS-UPDRS part 3 values, (4) common SD: 12, (5) correlation between baseline and follow-up MDS-UPDRS measurement: 0.8, (6) power: 80%, (7) significance level: two-sided 5%. Thus, we estimated that 87 participants were required for the trial. The phase 2 exenatide trial reported that attrition (withdrawal/lost to follow-up) was 5 out of 62 (8%) during the trial, and 2 out of 62 (3%) were excluded from the analysis as early withdrawal (within 12 weeks). According to the PIONEER 9 trial, which enrolled Japanese patients with T2DM, attrition due to adverse events in the oral semaglutide group was less than 3%.22 Assuming 10% attrition, 99 participants would be sufficient to detect significant differences between participants according to treatment allocation. Statistical analysis All study analyses will be done in accordance with a predefined statistical analysis plan. All analyses will be performed according to a modified intention-to-treat principle in accordance with the randomised intervention. The threshold for the analysis population will be the participants whose outcomes will be available. To analyse the effect of treatment allocation on the primary outcome and secondary endpoints where applicable, we will use the ANCOVA approach to adjust for stratification factors (Hoehn and Yahr stage) and baseline raw MDS-UPDRS part 3 values. For the primary analysis, if data at week 48 are missing, they will be carried forward using the baseline value. If data at week 36 are missing, they will be carried forward using the most recently available data. The Bonferroni method will be used for multiple comparisons adjustment. Sensitivity analysis will also be performed for the change from baseline in the OFF medication MDS-UPDRS part 3 score using a mixed model for repeated measures. For quantitative analysis of the DaTscan data, we will use statistical parametric mapping. Statistical analysis will be done by the ANCOVA approach to adjust for stratification factors, baseline differences in DaTscan signal and change in LED at the last visit. We will use Pearson’s correlation coefficient or Spearman’s rank correlation coefficient to investigate the possible relationship between the noted effects and potential confounding factors. A comparison of notable adverse events between the treatment groups will be done using the χ2 test, where applicable. Patient and public involvement Patients or the public were not involved in the design of our research. The results will be disseminated to patients in a lay summary format. Ethics and dissemination Ethics considerations The protocol was approved by the Pharmaceuticals and Medical Devices Agency of Japan. The study was approved by the institutional review boards (IRBs) of the University of Osaka Hospital (reference number: 229 004-A) and each study site (reference number: 04504001 at Hirosaki University Hospital, Ji-047 at Kindai University Hospital, 2022309 at Kyushu University Hospital, 31-23-0001 at Nagoya City University Hospital, 342006 at Nagoya University Hospital, 23-07 at Toho University Omori Medical Center and MA-001 at Toyonaka Municipal Hospital). The procedures are described in detail as follows. The protocol, protocol amendments, informed consent form (ICF), investigator’s brochure, and other relevant documents (eg, advertisements) were submitted to an IRB by the investigator and reviewed and approved by the IRB before the study was initiated at each site. Any amendments to the protocol will require IRB approval before the implementation of changes made to the study design, except for those necessary to eliminate immediate hazards to the study participants. The investigator will be responsible for the following: providing written summaries of the status of the study to the IRB annually or more frequently in accordance with the requirements, policies and procedures established by the IRB; notifying the IRB of severe adverse events or other significant safety findings as required by IRB procedures; providing oversight of the conduct of the study at the site; and adhering to the requirements of ICH guidelines, the IRB and all other applicable local regulations. Informed consent procedures The investigator or their representative will explain the nature of the study, including risks and benefits, to potential participants and answer all questions regarding the study. Potential participants must be informed that their participation is voluntary. They would be required to sign a statement of informed consent that meets the requirements of local regulations, ICH GCP guidelines, privacy and data protection requirements where applicable, and the IRB or study centre (online supplemental material 1). The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study, and the date the written consent was obtained. An authorised person obtaining informed consent must also sign the ICF. Participants must be reconsented to the most current version of the ICFs during their participation in the study. A copy of each ICF must be provided to each participant. Separate consent will be obtained for secondary use of residual specimens and data following the same procedure (online supplemental material 2). Compensation for health hazards The clinical trial coordinator enrolls in insurance to compensate for any health damage suffered by the subjects. Dissemination The results will be disseminated in peer-reviewed journals, presented at scientific meetings and to patients in a lay summary format. Supplementary material Acknowledgements We are grateful to all patients participating in this trial. We express our gratitude to Novo Nordisk for reviewing the protocol and providing the investigational drug and placebo. We would like to thank Akiyo Ueshima, Kento Asano and other members of the Department of Medical Innovation, The University of Osaka Hospital, who provided their support to this trial. We would like to thank Editage (www.editage.jp) for English language editing. Footnotes Funding: This trial was funded by grants from the Japan Agency for Medical Research and Development (AMED) (grant number: JP21lk0201131 and JP22lk0201162). Novo Nordisk provided the investigational drug and placebo. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-112318). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. References Supplementary Materials